Eyenovia EYEN Stock
Eyenovia Price Chart
Eyenovia EYEN Financial and Trading Overview
| Eyenovia stock price | 0.53 USD |
| Previous Close | 2.81 USD |
| Open | 2.78 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 1100 |
| Day's Range | 2.62 - 2.8 USD |
| 52 Week Range | 1.5 - 5.85 USD |
| Volume | 362.23K USD |
| Avg. Volume | 497.2K USD |
| Market Cap | 100.33M USD |
| Beta (5Y Monthly) | 1.733098 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.5 USD |
EYEN Valuation Measures
| Enterprise Value | 99.32M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.1807232 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 6.3461537 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.991 |
Trading Information
Eyenovia Stock Price History
| Beta (5Y Monthly) | 1.733098 |
| 52-Week Change | 54.38% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.85 USD |
| 52 Week Low | 1.5 USD |
| 50-Day Moving Average | 3.81 USD |
| 200-Day Moving Average | 2.67 USD |
EYEN Share Statistics
| Avg. Volume (3 month) | 497.2K USD |
| Avg. Daily Volume (10-Days) | 278.21K USD |
| Shares Outstanding | 38M |
| Float | 31.04M |
| Short Ratio | 0.89 |
| % Held by Insiders | 22.42% |
| % Held by Institutions | 9.93% |
| Shares Short | 779.5K |
| Short % of Float | 2.45% |
| Short % of Shares Outstanding | 2.04% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -45.29% |
| Return on Equity (ttm) | -115.81% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -24887684 USD |
| Net Income Avi to Common (ttm) | -26410858 USD |
| Diluted EPS (ttm) | -0.73 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 18.47M USD |
| Total Cash Per Share (mrq) | 0.49 USD |
| Total Debt (mrq) | 11M USD |
| Total Debt/Equity (mrq) | 69.54 USD |
| Current Ratio (mrq) | 5.085 |
| Book Value Per Share (mrq) | 0.416 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -23879792 USD |
| Levered Free Cash Flow (ttm) | -16747411 USD |
Profile of Eyenovia
| Country | United States |
| State | NY |
| City | New York |
| Address | 295 Madison Avenue |
| ZIP | 10017 |
| Phone | 833 393 6684 |
| Website | https://www.eyenovia.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 41 |
Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Q&A For Eyenovia Stock
What is a current EYEN stock price?
Eyenovia EYEN stock price today per share is 0.53 USD.
How to purchase Eyenovia stock?
You can buy EYEN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eyenovia?
The stock symbol or ticker of Eyenovia is EYEN.
Which industry does the Eyenovia company belong to?
The Eyenovia industry is Biotechnology.
How many shares does Eyenovia have in circulation?
The max supply of Eyenovia shares is 47.25M.
What is Eyenovia Price to Earnings Ratio (PE Ratio)?
Eyenovia PE Ratio is now.
What was Eyenovia earnings per share over the trailing 12 months (TTM)?
Eyenovia EPS is -0.66 USD over the trailing 12 months.
Which sector does the Eyenovia company belong to?
The Eyenovia sector is Healthcare.
Eyenovia EYEN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}